Top Navigation

NEJM Editorial Advises Against Extended-Release Niacin

Extended-Release Niacin with LaropiprantPatients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level. This study examined the clinical efficacy

To gain access to this article and the rest of our extensive database of full-text articles, please register below or log in here.

Existing Users Log In
   
New User Registration
*Required field

, ,

Powered by Quadshot